SRY and neoplasm: The downregulation of miR-126 significantly inhibited tumor growth in HBs and reduced the proportion of CD44+ CD90+ CD133+ cells, increasing the expression of IL-6, Oct4, SRY, TGF-β, and β-catenin in mouse tumor tissues.